FDA rejects injectable Zyprexa – Regulators seek more data after some side effects seen in testing

Indianapolis Star

By John Russell

Eli Lilly and Co. has hit a roadblock in its efforts to extend the life of its top-selling product, the schizophrenia drug Zyprexa, which loses its patent protection against generic rivals in three years.

The Food and Drug Administration rejected Lilly’s application to sell a once-a-month injectable version of Zyprexa, the Indianapolis drug maker said Thursday. The move surprised Wall Street, pushing Lilly’s stock down 90 cents, or nearly 2 percent, to close at $50.93.

Several analysts had expected the new form of Zyprexa would ring up robust sales in coming years to help offset the loss of daily Zyprexa, which had sales last year of $4.7 billion.

Catherine Arnold, a drug analyst at Credit Suisse in New York, had projected that long-acting Zyprexa would deliver $500 million a year in sales for Lilly starting in 2010…

Advertisements

1 Comment

Filed under Uncategorized

One response to “FDA rejects injectable Zyprexa – Regulators seek more data after some side effects seen in testing

  1. Frankye Brooks

    Call the Pharma Cartel accountable for the harm they do to the human race!!!

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s